Boston Scientific this week announced positive data for its Eluvia drug-eluting vascular stent system.
Data presented this week included one-year results from the company’s Eminent trial, which showed superiority of the Eluvia stent compared to self-expanding bare metal stents (BMS) to treat patients with peripheral artery disease (PAD) and superficial femoral artery (SFA) or popliteal artery (PPA) lesions up to 210 mm in length.
The study enrolled 775 patients and had a primary patency rate of 85.4% versus 76.3% with BMS. It also demonstrated a “significantly greater rate” of sustained clinical improvement without reintervention at 83% for patients treated with the Eluvia stent compared to 76.6% for BMS treatment, according to the company. There was no significant difference in major adverse events or all-cause mortality rates between patients treated with the Eluvia stent and patients treated with BMS through one year.
“We are committed to meaningful clinical trials designed to evolve clinical practice, and on the heels of the positive Ranger II SFA data presented yesterday, we are pleased that the Eminent trial establishes the Eluvia stent as the first drug-eluting stent to demonstrate superior primary patency rates compared to bare metal stents in a head-to-head randomized trial,” Michael Jeff, chief medical officer and VP of clinical affairs, technology and innovation, said in a news release. “The breadth of our portfolio, as the only company offering both a drug-coated balloon and a drug-eluting stent for the treatment of patients with PAD, provides physicians with evidence-based and highly-differentiated treatment options.”
